Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
Crossref DOI link: https://doi.org/10.1007/s40256-016-0204-1
Published Online: 2016-11-23
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Athanasakis, Kostas
Boubouchairopoulou, Nadia
Karampli, Eleftheria
Tarantilis, Filippos
Savvari, Paraskevi
Bilitou, Aikaterini
Kyriopoulos, John
Funding for this research was provided by:
Pfizer Hellas
License valid from 2016-11-23